Quarterly report pursuant to Section 13 or 15(d)


3 Months Ended
Mar. 31, 2015
Equity [Abstract]  


On March 18, 2015, the Company announced the closing of an underwritten sale of 1,225,000 shares of its common stock, as well as 183,750 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters, at a public offering price of $8.00 per share, for gross proceeds of approximately $11.3 million. Net proceeds from this offering were approximately $10.2 million, net of underwriting discounts and offering expenses of approximately $1.1 million. The shares were sold under a shelf registration statement on Form S-3 (File No. 333-200638) that was declared effective by the SEC on December 23, 2014.


Equity Incentive Plan


The fair value of employee options granted was determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. The Company's employee stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. Because there has been minimal data for the Company's stock and very little historical experience with the Company's stock options, similar public companies and a pro rata percentage of the Company’s  common stock were used for calculating ADMA’s volatility for comparison and expectations as to the assumptions required for fair value computation using the Black-Scholes methodology.


  Three Months Ended Three Months Ended
  March 31, 2015 March 31, 2014
Expected term 6.3 years 6.3 years
Volatility 56-57% 63%
Dividend yield 0.0 0.0
Risk-free interest rate 1.49-1.90% 1.24-2.25%


Guidance for stock-based compensation requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company currently estimates there will be no material forfeitures of options.


The weighted average remaining contractual life of stock options outstanding and expected to vest at March 31, 2015 is 7.6 years.  The weighted average remaining contractual life of stock options exercisable at March 31, 2015 is 6.6 years.


A summary of the Company’s option activity under the Plan and related information is as follows:


    Three Months Ended  
    March 31, 2015  
    Shares     Price  
Outstanding at beginning of period     1,048,927     $ 7.24  
Forfeited     (835 )   $ 7.46  
Granted     230,000     $ 10.47  
Outstanding at end of period and expected to vest     1,278,092     $ 7.82  
Options exercisable     707,920     $ 6.96  



Stock-based compensation expense for the three months ended March 31, 2015 and 2014 is as follows:


    Three Months Ended  
    March 31,  
    2015     2014  
Research and development   $ 164,068     $ 55,529  
Plasma centers     11,033       8,726  
General and administrative     211,968       169,945  
Total stock based compensation expense   $ 387,069     $ 234,200  


As of March 31, 2015, the total compensation expense related to unvested options not yet recognized totaled $3,475,360. The weighted average vesting period over which the total compensation expense will be recorded related to unvested options not yet recognized at March 31, 2015 was approximately 3.0 years.